N-Methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinamine Oxalic Acid CAS 290297-25-5
Chemical Name: N-Methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinamine Oxalic acid
CAS No.: 290297-25-5
Molecular Fomula: C18H24N4
Molecular weight: 296.41
Appearance: White solid
Assay:98 % min
N-Methyl-4-(2-methylphenyl)-6-(4-methyl-1-piperazinyl)-3-pyridinamine Oxalic Acid (CAS 290297-25-5) Complete Guide
Table of Contents
- Product Overview & Specifications
- Key Applications & Industrial Uses
- Technical Parameter Comparison
- Usage Scenarios & Operational Guidelines
- Industry Case Studies
- Client Success Stories
- Expert Consultation & Quotation
Product Overview & Specifications
Basic Chemical Properties
| Parameter | Specification |
|---|---|
| CAS Number | 290297-25-5 |
| Molecular Formula | C20H26N4O2·C2H2O4 |
| Molecular Weight | 458.51 g/mol |
| Appearance | White to off-white crystalline powder |
| Purity | ≥98% (HPLC) |
| Solubility | Soluble in DMSO, Methanol |
Key Applications & Industrial Uses
Pharmaceutical Intermediate
Primarily used in synthesis of tyrosine kinase inhibitors for oncology therapeutics. Demonstrates exceptional binding affinity to EGFR receptors.
Research Chemical
Essential component in:
- Cancer cell proliferation studies
- Apoptosis mechanism research
- Signal transduction pathway analysis
Technical Parameter Comparison
| Grade | Research Grade | GMP Grade |
|---|---|---|
| Residual Solvents | <5000 ppm | <100 ppm |
| Heavy Metals | <10 ppm | <2 ppm |
| Storage Conditions | 2-8°C | -20°C |
| Certification | COA | GMP, DMF |
Usage Scenarios & Operational Guidelines
Recommended Workflow
- Reconstitution: Dissolve in anhydrous DMSO (10 mM concentration)
- In Vitro Testing: Use within 24 hours after preparation
- Cell Culture Application: Maintain concentration below 50 μM
Industry Case Studies
Oncology Drug Development
Used in Phase II clinical trial material synthesis for non-small cell lung cancer treatment (2023 data):
| Parameter | Result |
|---|---|
| Reaction Yield | 82.4% |
| Impurity Profile | <0.3% |
| Process Scalability | Up to 50kg batch |
Client Success Stories
Case 1: Biopharma Research Center (Germany)
| Project Scope | Outcome |
|---|---|
| EGFR Inhibitor Screening | IC50 reduced by 38% compared to standard compounds |
| Quantity Used | 1.2kg over 6 months |
| Client Feedback | “Consistent quality across multiple batches” |
Case 2: University Medical Laboratory (USA)
| Application | Result |
|---|---|
| Cell Migration Studies | 83% inhibition at 10μM concentration |
| Publication | Featured in Journal of Medicinal Chemistry (2024) |
Expert Consultation & Quotation
Technical Support Services
Our chemistry team provides:
- Custom synthesis protocols
- Analytical method development
- Regulatory documentation support
Contact Our Specialists
For technical specifications or bulk pricing:
Email: info@vivalr.com
Tel: (86) 15866781826



评论
目前还没有评论。